Completed PHASE3 INTERVENTIONAL 2-arm NCT04459325

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Sponsor: AO GENERIUM

Conditions COVID-19 Coronavirus Disease 2019

Interventions Best available care Tigerase® and best available care

Updated 6 times since 2020 Last updated: Oct 13, 2020 Started: Jun 1, 2020 Primary completion: Jul 20, 2020 Completion: Jul 20, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04459325, this PHASE3 trial focuses on COVID-19 and Coronavirus Disease 2019 and remains completed. Sponsored by AO GENERIUM, it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Aug 2020 — Nov 2020 [monthly]

Recruiting PHASE3

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AO GENERIUM

Data source: AO GENERIUM

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia